A novel treatment target for Parkinson's disease

Research output: Contribution to journalReview article

  • 7 Citations

Abstract

We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A.

LanguageEnglish (US)
Pages34-38
Number of pages5
JournalJournal of the Neurological Sciences
Volume347
Issue number1-2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Niacin
Parkinson Disease
NAD
Dopamine
Butyrates
NADP
Retina
Anti-Inflammatory Agents
Pathology
Inflammation
Skin

Keywords

  • GPR109A
  • HCAR2
  • HM74a
  • Inflammation
  • Niacin
  • Niacinamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

A novel treatment target for Parkinson's disease. / Wakade, Chandramohan; Chong, Raymond.

In: Journal of the Neurological Sciences, Vol. 347, No. 1-2, 01.01.2014, p. 34-38.

Research output: Contribution to journalReview article

@article{a6f60861bfa849ec9ad15684a84f0435,
title = "A novel treatment target for Parkinson's disease",
abstract = "We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A.",
keywords = "GPR109A, HCAR2, HM74a, Inflammation, Niacin, Niacinamide",
author = "Chandramohan Wakade and Raymond Chong",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jns.2014.10.024",
language = "English (US)",
volume = "347",
pages = "34--38",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A novel treatment target for Parkinson's disease

AU - Wakade,Chandramohan

AU - Chong,Raymond

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A.

AB - We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A.

KW - GPR109A

KW - HCAR2

KW - HM74a

KW - Inflammation

KW - Niacin

KW - Niacinamide

UR - http://www.scopus.com/inward/record.url?scp=84920053894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920053894&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2014.10.024

DO - 10.1016/j.jns.2014.10.024

M3 - Review article

VL - 347

SP - 34

EP - 38

JO - Journal of the Neurological Sciences

T2 - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -